Extraskeletal chondrosarcoma
Extraskeletal chondrosarcoma is a chondrosarcoma that occurs in soft tissues. It can be divided into myxoid, mesenchymal, and differentiated types. Since differentiated types are rare, only extraskeletal myxoid chondrosarcoma is introduced here.
-
Site of disease:
bone -
Infectious :
Not contagious -
Frequent population:
It is common in middle-aged men around 50 years old... -
Related symptoms:
Bone pain Endochondral ossification Pain -
Concurrent disease:
Related Drugs
Cisplatin for injection
Indication: It is the first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is the first-line treatment for SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is currently a commonly used regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. PVB (DDP, VLB, BLM) can treat most stage IV non-spermogenic testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used abroad for local radiotherapy of stage IV inoperable NSCLC, which can provide
Manufacturer:
Qilu Pharmaceutical Co., Ltd.
Related Ingredients